Get the Stockscreener App
1.68
2.33%
-0.04
Pre-market:
1.68
Pliant Therapeutics Inc stock is traded at $1.68, with a volume of 498.44K.
It is down -2.33% in the last 24 hours and up +11.26% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.72
Open:
$1.69
24h Volume:
498.44K
Relative Volume:
0.64
Market Cap:
$103.13M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.5437
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+5.00%
1M Performance:
+11.26%
6M Performance:
+23.53%
1Y Performance:
-86.93%
1-Day Range:
$1.67
$1.785
1-Week Range:
$1.56
$1.815
52-Week Range:
$1.1001
$15.80
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.68 | 105.69M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
What high frequency data says about Pliant Therapeutics Inc.Trade Exit Summary & AI Based Buy and Sell Signals - newser.com
Does Pliant Therapeutics Inc. show high probability of reboundMarket Performance Report & Free Accurate Trade Setup Notifications - newser.com
Is Pliant Therapeutics Inc. stock near bottom after decline2025 Stock Rankings & Community Consensus Stock Picks - newser.com
Why global investors buy Pliant Therapeutics Inc. (9PT) stockTrend Reversal & Safe Capital Growth Trade Ideas - newser.com
How rising interest rates impact Pliant Therapeutics Inc. stockIPO Watch & Community Driven Trade Alerts - newser.com
Heatmap analysis for Pliant Therapeutics Inc. and competitors2025 Volume Leaders & Community Verified Watchlist Alerts - newser.com
Chart overlay techniques for tracking Pliant Therapeutics Inc.Weekly Trend Recap & Real-Time Stock Entry Alerts - newser.com
Square Four Projects India Limited Earnings Review What Investors Need to KnowMomentum Stock Picks & Learn to Pick Stocks in Under 10 Minutes - earlytimes.in
Can Pliant Therapeutics Inc. stock maintain operating marginsLong Setup & Expert Verified Movement Alerts - newser.com
Why Pliant Therapeutics Inc. stock is in analyst buy zone2025 Institutional Moves & Verified Entry Point Signals - newser.com
Is Pliant Therapeutics Inc a good long term investmentMoving Average Strategies & Take Advantage of Momentum Stocks - earlytimes.in
Why Pliant Therapeutics Inc. (9PT) stock could be top winnerJuly 2025 Action & Pattern Based Trade Signal System - newser.com
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsJuly 2025 Institutional & Weekly Breakout Watchlists - newser.com
Why Pliant Therapeutics Inc. stock is popular among millennialsLayoff News & High Return Stock Watch Alerts - Fundação Cultural do Pará
Will Pliant Therapeutics Inc. stock deliver shareholder valueMarket Volume Report & Risk Adjusted Swing Trade Ideas - newser.com
Why Pliant Therapeutics Inc. stock is favored by top institutionsWeekly Profit Recap & Reliable Volume Spike Trade Alerts - newser.com
What indicators show strength in Pliant Therapeutics Inc.2025 Key Highlights & Daily Profit Maximizing Trade Tips - newser.com
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):